Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide

International Journal of Cancer

Volumn 85, Issue 2, 2000, Pages 236-242

  El Shami, Khaled M ^a   Tirosh, Boaz ^a   Popovic, Dan ^a   Carmon, Lior ^a   Tzehoval, Esther ^a   Vadai, Ezra ^a   Feldman, Michael ^a   Eisenbach, Lea ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2; MUT 1 ANTIGEN; PROTEASOME; PROTEASOME INHIBITOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOLOGY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FIBROBLAST CULTURE; IMMUNOGENICITY; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034650796     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000115)85:2<236::AID-IJC14>3.0.CO;2-5     Document Type: Article

References (25)

1. BANNERJI, R., ARROYO, C.D., CORDON-CARDO, C. and GILBOA, E., The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol., 152, 2324-2332 (1994).
2. + CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties. J. Immunol., 160, 2433-2441 (1998).
3. COUX, O., TANAKA, K. and GOLDBERG, L.A., Structure and functions of the 20S and 26S proteasomes. Ann. Rev. Biochem., 65, 801-847 (1996).
4. ENGELHARD, V.H., Structures of peptides associated with MHC class I molecules. Curr. Opinion Immunol., 6, 13-23 (1994).
5. FALK, K., ROTZSCHKE, S., STEVANOVIC, S., JUNG, G. and RAMMENSEE, H., Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.), 51, 290-296 (1991).
6. GOLDBERG, A.L., GACZYNSKA, M., GRANT, E., MICHALIK, M. and ROCK, K.L., Functions of the proteasome in antigen presentation. Cold Spring Harbor Symp. quant. Biol., 50, 47-61 (1995).
7. GOLDSTEIN, S., Replicative senescence: the human fibroblast comes of age. Science, 249, 1129-1133 (1990).
8. HARDING, C.V., FRANCE, J., SONG, R., FARAH, J.M., CHATTERJEE, S., IQBAL, M. and SIMON, R., Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen processing pathway. J. Immunol., 155, 1767-1775 (1995).
9. HOOIJBERG, E., VISSEREN, M.J.W., VAN DEN BERK, P.C.M., JELLEMA, A.P., ROMEIJN, P., SEIN, J.J., VAN DER VOORT, E.I.H., HEKMAN, A., OSSENDORP, F. and MELILE, C.J.M., Lysis of syngeneic B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide. J. Immunother., 19, 346-453 (1996).
10. KÜNDIG, T.M., BACHMANN, M.F., DIPAOLO, C., SIMARD, J.J.L., BATTGAY, M., LOTHER, H., GESSNER, A., KÜHLKE, K., OHASHI, P.S., HENGARTNER, H., and ZINKERNAGEL, R.M., Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science, 268, 1343-1347 (1995).
11. MANDELBOIM, O., BERKE, G., FRIDKIN, M., FELDMAN, M., EISENSTEIN, M. and EISENBACH, L., CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature (Lond.), 369, 67-71 (1994).
12. MANDELBOIM, O., VADAI, E., FRIDKIN, M., KATZ-HILLEL, A., FELDMAN, M., BERKE, G. and EISENBACH, L., Regression of established murine lung carcinoma metastases following vaccination with tumor-associated antigen peptide. Nature (Med.), 1, 1179-1184 (1995).
13. MAYORDOMO, J.I., ZORMA, T., STORKUS, W.J., ZITVOGEL, L., CELLUZZI, C., FALO, L.D., MELIEF, C.J.M., ILSTAD, S.T., KAST, W.M., DELEO, A.B. and LOTZE, M.T., Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature (Med.), 1, 1297-1301 (1995).
14. MELIEF, C.J.M., OFFRINGA, R., TOES, R.E.T. and KAST, W.M., Peptide-based cancer vaccine. Curr. Opinion Immunol., 8, 651-658 (1996).
15. b haplotype reveal genetic control of isotype expression. J. Immunol., 126, 317-321 (1981).
16. PARKHURST, M.R., SALGALLER, M.L., SOUTHWOOD, S., ROBBINS, P.P., SETTE, A. and ROSENBERG, S.A., Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157, 2539-2549 (1996).
17. b gene. Proc. nat. Acad. Sci. (Wash.), 84, 4463-4470 (1988).
18. PORGADOR, A., GANSBACHER, B., BANNERJI, R., TZEHOVAL, E., GILBOA, E., FELDMAN, M. and EISENBACH, L., Antimetastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int. J. Cancer, 53, 471-477 (1993).
19. RAMMENSEE, H-G., FRIEDE, T. and STEVANOVIC, S., MHC ligands and peptide motifs: first listing, Immunogenetics, 41, 178-182 (1995).
20. RAS, E., VAN DER BERG, S.H., ZEGVELD, S.T., BRANDT, R.M., KUPPEN, P.J., OFFRINGA, R., WARNARR, S.O., VAN DE VELDE, C.G. and MELIEF, C.J., Identification of HLA-A*0201 restricted CTL epitopes from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum. Immunol., 53, 81-89 (1997).
21. ROCK, K.L., GRAMM, C., ROTHSTEIN, L., CLARK, K., STEIN, R., DICK, L., HWANG, D. and GOLDBERG, A.L., Inhibotors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78, 761-771 (1994).
22. ROSENBERG, S.A., YANG, J.C., SCHWARZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., DUDLEY, M.E., SCHWARZ, S.L., SPIESS, P.J., HELLSTROM, I. and HELLSTRÖM, K.E., T cell immunity to tumor antigens. Crit. Rev. Immunol., 18, 1-6 (1998).
23. SETTE, A. and 16 OTHERS, The relationship between class I binding affinity and immunogenicity of potential cytotoxic T lymphocyte epitopes. J. Immunol., 153, 5586-5592 (1996).
24. TOURDOT, S., OUKKA, M., MANUGUERRA, J.C., MAGAFA, V., VERGNON, I., RICHE, N., BRULEY-ROSSET, M., CORDOPATIS, P. and KOSMATOPOULOS, K., Clinique peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. J. Immunol., 159, 2391-2398 (1997).
25. YORK, I.A. and ROCK, K.L., Antigen processing and presentation by the class I major histocompatibility complex. Ann. Rev. Immunol., 14, 369-397 (1996).